{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:16:19Z","timestamp":1768011379431,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was supported by a grant from AstraZeneca."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lifestyle factors are important drivers of chronic diseases, including cardiovascular syndromes, with low grade inflammation as a central player. Attenuating myeloperoxidase (MPO) activity, an inflammatory enzyme associated with obesity, hypertension and heart failure, could have protective effects on multiple organs. Herein, the effects of the novel oral available MPO inhibitor AZM198 were studied in an obese\/hypertensive mouse model which displays a cardiac phenotype. Eight week old male C57BL6\/J mice received 16 weeks of high fat diet (HFD) combined with angiotensin II (AngII) infusion during the last 4 weeks, with low fat diet and saline infusion as control. Treated animals showed therapeutic AZM198 levels (2.1\u2009\u00b5M), corresponding to 95% MPO inhibition. AZM198 reduced elevated circulating MPO levels in HFD\/AngII mice to normal values. Independent of food intake, bodyweight increase and fat accumulation were attenuated by AZM198, alongside with reduced visceral adipose tissue (VAT) inflammation and attenuated severity of nonalcoholic steatohepatitis. The HFD\/AngII perturbation caused impaired cardiac relaxation and contraction, and increased cardiac hypertrophy and fibrosis. AZM198 treatment did, however, not improve these cardiac parameters. Thus, AZM198 had positive effects on the main lipid controlling tissues in the body, namely adipose tissue and liver. This did, however, not directly result in improved cardiac function.<\/jats:p>","DOI":"10.1038\/s41598-019-55263-y","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T11:03:32Z","timestamp":1575975812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Pharmacological myeloperoxidase (MPO) inhibition in an obese\/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling"],"prefix":"10.1038","volume":"9","author":[{"given":"Arnold","family":"Piek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debby P. Y.","family":"Koonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth-Maria","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva L.","family":"Lindtstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Micha\u00eblsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-9140","authenticated-orcid":false,"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3292-6302","authenticated-orcid":false,"given":"Herman H. W.","family":"Sillj\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"55263_CR1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40273-014-0243-x","volume":"33","author":"A Hruby","year":"2015","unstructured":"Hruby, A. & Hu, F. B. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics 33, 673\u2013689 (2015).","journal-title":"Pharmacoeconomics"},{"key":"55263_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills, K. T. et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation 134, 441\u2013450 (2016).","journal-title":"Circulation"},{"key":"55263_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.diabres.2013.11.007","volume":"103","author":"T Tamayo","year":"2014","unstructured":"Tamayo, T. et al. Diabetes in Europe: an update. Diabetes Res. Clin. Pract. 103, 206\u2013217 (2014).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"55263_CR4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37, 2129\u20132200 (2016).","journal-title":"Eur. Heart J."},{"key":"55263_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/heart.89.10.1127","volume":"89","author":"RS Vasan","year":"2003","unstructured":"Vasan, R. S. Cardiac function and obesity. Heart 89, 1127\u20131129 (2003).","journal-title":"Heart"},{"key":"55263_CR6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","volume":"116","author":"JE Hall","year":"2015","unstructured":"Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z. & Hall, M. E. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ. Res. 116, 991\u20131006 (2015).","journal-title":"Circ. Res."},{"key":"55263_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2174\/1570161112666140423221008","volume":"12","author":"D Prieto","year":"2014","unstructured":"Prieto, D., Contreras, C. & Sanchez, A. Endothelial dysfunction, obesity and insulin resistance. Curr. Vasc. Pharmacol. 12, 412\u2013426 (2014).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"55263_CR8","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1093\/eurheartj\/ehn387","volume":"29","author":"GR Hajer","year":"2008","unstructured":"Hajer, G. R., van Haeften, T. W. & Visseren, F. L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 29, 2959\u20132971 (2008).","journal-title":"Eur. Heart J."},{"key":"55263_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nature05487","volume":"444","author":"LF Van Gaal","year":"2006","unstructured":"Van Gaal, L. F., Mertens, I. L. & De Block, C. E. Mechanisms linking obesity with cardiovascular disease. Nature 444, 875\u2013880 (2006).","journal-title":"Nature"},{"key":"55263_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.113.001878","volume":"128","author":"JS Burchfield","year":"2013","unstructured":"Burchfield, J. S., Xie, M. & Hill, J. A. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation 128, 388\u2013400 (2013).","journal-title":"Circulation"},{"key":"55263_CR11","first-page":"152","volume":"15","author":"C Savoia","year":"2006","unstructured":"Savoia, C. & Schiffrin, E. L. Inflammation in hypertension. Curr. Opin. Nephrol. Hypertens. 15, 152\u2013158 (2006).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"55263_CR12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1515\/hmbci-2013-0025","volume":"15","author":"G Lastra","year":"2013","unstructured":"Lastra, G. & Sowers, J. R. Obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-aldosterone system. Horm. Mol. Biol. Clin. Investig. 15, 49\u201357 (2013).","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"55263_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/bmj.321.7255.199","volume":"321","author":"J Danesh","year":"2000","unstructured":"Danesh, J. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321, 199\u2013204 (2000).","journal-title":"BMJ"},{"key":"55263_CR14","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.metabol.2004.02.004","volume":"53","author":"JS Yudkin","year":"2004","unstructured":"Yudkin, J. S. et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 53, 852\u2013857 (2004).","journal-title":"Metabolism"},{"key":"55263_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/eurheartj\/ehu067","volume":"35","author":"M Komajda","year":"2014","unstructured":"Komajda, M. & Lam, C. S. Heart failure with preserved ejection fraction: a clinical dilemma. Eur. Heart J. 35, 1022\u20131032 (2014).","journal-title":"Eur. Heart J."},{"key":"55263_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus, W. J. & Tschope, C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62, 263\u2013271 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"55263_CR17","doi-asserted-by":"publisher","first-page":"28403","DOI":"10.1074\/jbc.M304739200","volume":"278","author":"X Fu","year":"2003","unstructured":"Fu, X., Kassim, S. Y., Parks, W. C. & Heinecke, J. W. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J. Biol. Chem. 278, 28403\u201328409 (2003).","journal-title":"J. Biol. Chem."},{"key":"55263_CR18","doi-asserted-by":"publisher","first-page":"41279","DOI":"10.1074\/jbc.M106958200","volume":"276","author":"X Fu","year":"2001","unstructured":"Fu, X., Kassim, S. Y., Parks, W. C. & Heinecke, J. W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J. Biol. Chem. 276, 41279\u201341287 (2001).","journal-title":"J. Biol. Chem."},{"key":"55263_CR19","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/cmi.12312","volume":"16","author":"WM Nauseef","year":"2014","unstructured":"Nauseef, W. M. Myeloperoxidase in human neutrophil host defence. Cell. Microbiol. 16, 1146\u20131155 (2014).","journal-title":"Cell. Microbiol."},{"key":"55263_CR20","doi-asserted-by":"publisher","unstructured":"Tromp, J. et al. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction. J. Am. Heart Assoc. 6, https:\/\/doi.org\/10.1161\/JAHA.116.003989 (2017).","DOI":"10.1161\/JAHA.116.003989"},{"key":"55263_CR21","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1161\/HYPERTENSIONAHA.109.147231","volume":"55","author":"LP Van der Zwan","year":"2010","unstructured":"Van der Zwan, L. P. et al. Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. Hypertension 55, 1366\u20131372 (2010).","journal-title":"Hypertension"},{"key":"55263_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4093\/dmj.2015.39.1.59","volume":"39","author":"A Gomez Garcia","year":"2015","unstructured":"Gomez Garcia, A., Rivera Rodriguez, M., Gomez Alonso, C., Rodriguez Ochoa, D. Y. & Alvarez Aguilar, C. Myeloperoxidase is associated with insulin resistance and inflammation in overweight subjects with first-degree relatives with type 2 diabetes mellitus. Diabetes Metab. J. 39, 59\u201365 (2015).","journal-title":"Diabetes Metab. J."},{"key":"55263_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.amjcard.2006.04.018","volume":"98","author":"WH Tang","year":"2006","unstructured":"Tang, W. H. et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am. J. Cardiol. 98, 796\u2013799 (2006).","journal-title":"Am. J. Cardiol."},{"key":"55263_CR24","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.jacc.2007.02.053","volume":"49","author":"WH Tang","year":"2007","unstructured":"Tang, W. H. et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J. Am. Coll. Cardiol. 49, 2364\u20132370 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"55263_CR25","first-page":"884","volume":"10","author":"Y Michowitz","year":"2008","unstructured":"Michowitz, Y. et al. Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure. Isr. Med. Assoc. J. 10, 884\u2013888 (2008).","journal-title":"Isr. Med. Assoc. J."},{"key":"55263_CR26","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2353\/ajpath.2009.080999","volume":"175","author":"SS Rensen","year":"2009","unstructured":"Rensen, S. S. et al. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am. J. Pathol. 175, 1473\u20131482 (2009).","journal-title":"Am. J. Pathol."},{"key":"55263_CR27","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1089\/ars.2014.6108","volume":"23","author":"B Pulli","year":"2015","unstructured":"Pulli, B. et al. Myeloperoxidase-Hepatocyte-Stellate Cell Cross Talk Promotes Hepatocyte Injury and Fibrosis in Experimental Nonalcoholic Steatohepatitis. Antioxid. Redox Signal. 23, 1255\u20131269 (2015).","journal-title":"Antioxid. Redox Signal."},{"key":"55263_CR28","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.jss.2011.01.056","volume":"169","author":"AD Tevar","year":"2011","unstructured":"Tevar, A. D. et al. The effect of hepatic ischemia reperfusion injury in a murine model of nonalcoholic steatohepatitis. J. Surg. Res. 169, e7\u201314 (2011).","journal-title":"J. Surg. Res."},{"key":"55263_CR29","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.2337\/db14-0026","volume":"63","author":"Q Wang","year":"2014","unstructured":"Wang, Q. et al. Myeloperoxidase deletion prevents high-fat diet-induced obesity and insulin resistance. Diabetes 63, 4172\u20134185 (2014).","journal-title":"Diabetes"},{"key":"55263_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nm.2124","volume":"16","author":"V Rudolph","year":"2010","unstructured":"Rudolph, V. et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat. Med. 16, 470\u2013474 (2010).","journal-title":"Nat. Med."},{"key":"55263_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1161\/CIRCRESAHA.117.310870","volume":"121","author":"M Mollenhauer","year":"2017","unstructured":"Mollenhauer, M. et al. Myeloperoxidase Mediates Postischemic Arrhythmogenic Ventricular Remodeling. Circ. Res. 121, 56\u201370 (2017).","journal-title":"Circ. Res."},{"key":"55263_CR32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1084\/jem.20021426","volume":"197","author":"AT Askari","year":"2003","unstructured":"Askari, A. T. et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J. Exp. Med. 197, 615\u2013624 (2003).","journal-title":"J. Exp. Med."},{"key":"55263_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jacbts.2016.09.004","volume":"1","author":"M Ali","year":"2016","unstructured":"Ali, M. et al. Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction. JACC Basic Transl. Sci. 1, 633\u2013643 (2016).","journal-title":"JACC Basic Transl. Sci."},{"key":"55263_CR34","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1093\/eurheartj\/ehy419","volume":"39","author":"I Rashid","year":"2018","unstructured":"Rashid, I. et al. Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque. Eur. Heart J. 39, 3301\u20133310 (2018).","journal-title":"Eur. Heart J."},{"key":"55263_CR35","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.freeradbiomed.2015.10.398","volume":"89","author":"H Bjornsdottir","year":"2015","unstructured":"Bjornsdottir, H. et al. Neutrophil NET formation is regulated from the inside by myeloperoxidase-processed reactive oxygen species. Free Radic. Biol. Med. 89, 1024\u20131035 (2015).","journal-title":"Free Radic. Biol. Med."},{"key":"55263_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmed.2007.12.003","volume":"14","author":"F Marra","year":"2008","unstructured":"Marra, F., Gastaldelli, A., Svegliati Baroni, G., Tell, G. & Tiribelli, C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med. 14, 72\u201381 (2008).","journal-title":"Trends Mol. Med."},{"key":"55263_CR37","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/hep.23594","volume":"51","author":"BQ Starley","year":"2010","unstructured":"Starley, B. Q., Calcagno, C. J. & Harrison, S. A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51, 1820\u20131832 (2010).","journal-title":"Hepatology"},{"key":"55263_CR38","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.7150\/thno.26055","volume":"8","author":"W Du","year":"2018","unstructured":"Du, W. et al. Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. Theranostics 8, 4155\u20134169 (2018).","journal-title":"Theranostics"},{"key":"55263_CR39","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk, J. et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 33, 1635\u20131701 (2012).","journal-title":"Eur. Heart J."},{"key":"55263_CR40","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1128\/IAI.67.4.1828-1836.1999","volume":"67","author":"Y Aratani","year":"1999","unstructured":"Aratani, Y. et al. Severe impairment in early host defense against Candida albicans in mice deficient in myeloperoxidase. Infect. Immun. 67, 1828\u20131836 (1999).","journal-title":"Infect. Immun."},{"key":"55263_CR41","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","volume":"51","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini, E., Sullivan, S. & Klein, S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51, 679\u2013689 (2010).","journal-title":"Hepatology"},{"key":"55263_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2217\/17460875.3.5.545","volume":"3","author":"BK Surmi","year":"2008","unstructured":"Surmi, B. K. & Hasty, A. H. Macrophage infiltration into adipose tissue: initiation, propagation and remodeling. Future Lipidol. 3, 545\u2013556 (2008).","journal-title":"Future Lipidol."},{"key":"55263_CR43","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1161\/CIRCULATIONAHA.105.542340","volume":"112","author":"N Vasilyev","year":"2005","unstructured":"Vasilyev, N. et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 112, 2812\u20132820 (2005).","journal-title":"Circulation"},{"key":"55263_CR44","doi-asserted-by":"publisher","first-page":"37578","DOI":"10.1074\/jbc.M111.266981","volume":"286","author":"AK Tiden","year":"2011","unstructured":"Tiden, A. K. et al. 2-Thioxanthines are Mechanism-Based Inactivators of Myeloperoxidase that Block Oxidative Stress during Inflammation. J. Biol. Chem. 286, 37578\u201337589 (2011).","journal-title":"J. Biol. Chem."},{"key":"55263_CR45","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/10408363.2018.1460576","volume":"55","author":"A Piek","year":"2018","unstructured":"Piek, A., Du, W., de Boer, R. A. & Sillje, H. H. W. Novel heart failure biomarkers: why do we fail to exploit their potential? Crit. Rev. Clin. Lab. Sci. 55, 246\u2013263 (2018).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"55263_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","volume":"6","author":"L Yu","year":"2013","unstructured":"Yu, L. et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ. Heart Fail. 6, 107\u2013117 (2013).","journal-title":"Circ. Heart Fail."},{"key":"55263_CR47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/cvr\/cvw161","volume":"111","author":"HG Booij","year":"2016","unstructured":"Booij, H. G. et al. Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia\/reperfusion injury but does not influence heart failure development. Cardiovasc. Res. 111, 217\u2013226 (2016).","journal-title":"Cardiovasc. Res."},{"key":"55263_CR48","doi-asserted-by":"crossref","unstructured":"Hagdorn, Q. A. J. et al. A novel method optimizing the normalization of cardiac parameters in small animal models: the importance of dimensional indexing. Am. J. Physiol. Heart Circ. Physiol. (2019).","DOI":"10.1152\/ajpheart.00182.2019"},{"key":"55263_CR49","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55263-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55263-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55263-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T10:43:29Z","timestamp":1722163409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55263-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["55263"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-55263-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"assertion":[{"value":"17 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.L. and E.M. are employees of AstraZeneca, R&D, M\u00f6lndal, Sweden.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18765"}}